Filing 2025 Q2 compared to 2025 Q1 by default. Changes are calculated vs the previous SEC filing.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
Person Signing this Report on Behalf of Reporting Manager:
Name
Title
City, State
Date
Roderick Wong
Managing Partner
New York, New York
14 Aug 2025
The number of shares of Beta Bionics, Inc. ("Beta Bionics") common stock reported herein differs by 679 shares from the number reported in the Form 13F for March 31, 2025. This difference is as a result of the final determination of the number of shares received upon net exercise of warrants and the cash-out of certain fractional shares in connection with Beta Bionics initial public offering, and does not reflect the disposition by the Reporting Person of any shares of common stock of Beta Bionics.
We use cookies and similar technologies to provide certain features, enhance
the user experience and deliver content that is relevant to your interests.
Depending on their purpose, analysis and marketing cookies may be used in
addition to technically necessary cookies. By clicking on "Agree and
continue", you declare your consent to the use of the aforementioned cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.